US-based nutrition technology company L-Nutra announced that its Fasting Mimicking Nutrition Program showed positive outcomes for patients with type 2 diabetes in a recent study.
Researchers from the Heidelberg University Hospital, Germany have conducted a study on the company’s fasting-mimicking diet (FMD).
In their study, FMD was found to improve microalbuminuria, markers of insulin resistance, lipid oxidation, and senescence, and show potential benefits for people with type 2 diabetes.
Also, the study results showed that FMD is safe and well-tolerated when used together with intensive diabetes care.
L-Nutra said that it is the first randomised controlled trial to evaluate the clinical impact of FMD in type 2 diabetes patients.
L-Nutra CEO and chairman Joseph Antoun said: “L-Nutra is the leading Nutrition technology company with scientifically tested nutrition solutions to enhance healthy longevity while aiming to reverse major chronic diseases such as diabetes with its patented fasting-mimicking technology.
“This nutritional intervention, aimed at targeting the root cause of diabetes, makes us stand out from most current medical interventions that are limited to targeting glycemic control and symptoms.”
The study recruited 40 volunteers with type 2 diabetes who had protein in their urine, which is a sign of diabetic kidney disease, that may lead to end-stage kidney disease.
In the study, the participants received a five-day FMD per month for six consecutive months compared to a control group, who received a five-day Mediterranean Diet.
The FMD group experienced a significant reduction in their urinary albumin-to-creatinine ratio (UACR) when compared to patients in the control group.
The participants had a significant reduction in body weight, a 1.4% decrease in haemoglobin A1C, and a 59% improvement in HOMA-IR, a marker of insulin resistance, at six months.
The participants in the FMD group have seen a 67% reduction in antihyperglycemic medication compared to 21% for Mediterranean Diet group, at the end of the study.
L-Nutra intends to further evaluate its metabolic restoration program for type 2 diabetes patients, who wish to control diabetes without surgery, medications, or deteriorating health.
L-Nutra chief medical officer and Harvard Joslin Diabetes Centre former vice president William Hsu said: “For a diabetes program to effectively impact the daily lives of patients, safety, efficacy, and adherence are equally important.
“With these wide-ranging results, we have feasibility data to suggest that Fasting-Mimicking Nutrition Program, combined with personalized nutrition consultation, can be safely and effectively integrated into clinical practice to complement current practice.”
